Our last report on the company is from late 2018 where we dropped coverage on the name as its promised turnaround had not transpired and there were better opportunities at the time. CPH today remains focused as a specialty pharmaceutical company with a diverse portfolio, largely within dermatology, but its focus is now concentrated on product growth and profitability in dermatology and other high-potential areas.
Its current growth strategy is focused on integrating new acquisitions like Natroba, an anti-parasitic treatment, and getting regulatory approval for MOB-015. Despite the setbacks with its nail fungus drug, it remains a priority for the company.
As we have dropped coverage on the name, there are no immediate plans for a report, but as names become interesting again, we will consider new ideas for company coverage.